FKALX | VEXRX | FKALX / VEXRX | |
Total Expense Ratio | 0.89 | 0.34 | 262% |
Annual Report Gross Expense Ratio | 0.92 | 0.34 | 271% |
Fund Existence | 8 years | 23 years | - |
Gain YTD | -13.871 | -14.722 | 94% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 0 | 50000 | - |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 2.85B | 19.8B | 14% |
Annual Yield % from dividends | 1.68 | 0.56 | 298% |
Returns for 1 year | -10.95 | -12.82 | 85% |
Returns for 3 years | -7.89 | -9.40 | 84% |
Returns for 5 years | 4.20 | 15.80 | 27% |
Returns for 10 years | N/A | -1.76 | - |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
XBI | 79.10 | 1.46 | +1.88% |
SPDR® S&P Biotech ETF | |||
CHI | 9.78 | 0.17 | +1.77% |
Calamos Convertible Opportunities and Income Fund | |||
SBIO | 28.02 | 0.45 | +1.63% |
ALPS Medical Breakthroughs ETF | |||
BCDF | 28.54 | 0.12 | +0.44% |
Horizon Kinetics Blockchain Dev ETF | |||
FEP | 41.67 | -0.06 | -0.14% |
First Trust Europe AlphaDEX® ETF |